250 related articles for article (PubMed ID: 34068398)
1. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance.
Marin JJG; Sanchon-Sanchez P; Cives-Losada C; Del Carmen S; González-Santiago JM; Monte MJ; Macias RIR
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34068398
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
Gutiérrez-Larrañaga M; González-López E; Roa-Bautista A; Rodrigues PM; Díaz-González Á; Banales JM; López-Hoyos M; Santos-Laso A; Crespo J
Liver Cancer; 2021 Nov; 10(6):545-560. PubMed ID: 34950178
[TBL] [Abstract][Full Text] [Related]
3. Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models.
Zheng Q; Zhang B; Li C; Zhang X
Front Oncol; 2022; 12():850732. PubMed ID: 35372014
[TBL] [Abstract][Full Text] [Related]
4. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
5. The significance of genetics for cholangiocarcinoma development.
Maroni L; Pierantonelli I; Banales JM; Benedetti A; Marzioni M
Ann Transl Med; 2013 Oct; 1(3):28. PubMed ID: 25332972
[TBL] [Abstract][Full Text] [Related]
6. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
7. Cancer review: Cholangiocarcinoma.
Ghouri YA; Mian I; Blechacz B
J Carcinog; 2015; 14():1. PubMed ID: 25788866
[TBL] [Abstract][Full Text] [Related]
8. The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma.
Vaquero J; Lobe C; Tahraoui S; Clapéron A; Mergey M; Merabtene F; Wendum D; Coulouarn C; Housset C; Desbois-Mouthon C; Praz F; Fouassier L
Clin Cancer Res; 2018 Sep; 24(17):4282-4296. PubMed ID: 29716918
[No Abstract] [Full Text] [Related]
9. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma.
Balasubramanian B; Venkatraman S; Myint KZ; Janvilisri T; Wongprasert K; Kumkate S; Bates DO; Tohtong R
Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33440754
[TBL] [Abstract][Full Text] [Related]
10. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
11. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma.
Lu X; Green BL; Xie C; Liu C; Chen X
JHEP Rep; 2023 Jul; 5(7):100723. PubMed ID: 37229173
[TBL] [Abstract][Full Text] [Related]
13. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract][Full Text] [Related]
14. Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma.
Zhao LM; Shi AD; Yang Y; Liu ZL; Hu XQ; Shu LZ; Tang YC; Zhang ZL
Front Oncol; 2023; 13():1140103. PubMed ID: 37064120
[TBL] [Abstract][Full Text] [Related]
15. Chemoresistance and chemosensitization in cholangiocarcinoma.
Marin JJG; Lozano E; Herraez E; Asensio M; Di Giacomo S; Romero MR; Briz O; Serrano MA; Efferth T; Macias RIR
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1444-1453. PubMed ID: 28600147
[TBL] [Abstract][Full Text] [Related]
16. Cordycepin Inhibits Cancer Cell Proliferation and Angiogenesis through a DEK Interaction via ERK Signaling in Cholangiocarcinoma.
Liu T; Zhu G; Yan W; Lv Y; Wang X; Jin G; Cui M; Lin Z; Ren X
J Pharmacol Exp Ther; 2020 May; 373(2):279-289. PubMed ID: 32102917
[TBL] [Abstract][Full Text] [Related]
17. Protein Kinases as Targets for Opisthorchis viverrini- Associated Cholangiocarcinoma Therapy.
Loilome W; Dokduang H
Curr Pharm Des; 2017 Nov; 23(29):4281-4289. PubMed ID: 28699535
[TBL] [Abstract][Full Text] [Related]
18. Future directions in the treatment of cholangiocarcinoma.
Zhu AX
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
[TBL] [Abstract][Full Text] [Related]
19. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.
Fouassier L; Marzioni M; Afonso MB; Dooley S; Gaston K; Giannelli G; Rodrigues CMP; Lozano E; Mancarella S; Segatto O; Vaquero J; Marin JJG; Coulouarn C
Liver Int; 2019 May; 39 Suppl 1():43-62. PubMed ID: 30903728
[TBL] [Abstract][Full Text] [Related]
20. Molecular pathways and targeted therapy in cholangiocarcinoma.
Dabney RS; Khalife M; Shahid K; Phan AT
Clin Adv Hematol Oncol; 2019 Nov; 17(11):630-637. PubMed ID: 31851165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
